Search

Blog

We constantly analyse the legislation and regulatory information related to a specific medicine in order to appraise the context in which the company operates

We put all our knowledge into play to anticipate risks and seize every opportunity, but above all to understand the rules of the game and display our creativity with them. We spread material and information proceeding from our investigation into medicines governance and regulatory science. In fact, we deem it necessary to be aware of the complexity of the results of research, regulation and drug policy in order to be able to work in a cultural ecosystem aiming both at promoting research outcomes that are useful to patients and at encouraging politicians to protect people’s health. The wider the knowledge of each interest group, the greater their ability to interact and achieve transparency of procedures and health protection.

  • All
  • Scenario analysis
  • Notes
  • Drug Policy
  • Rare Diseases
  • Mapping
  • Team Pharma Value
All
  • All
  • Scenario analysis
  • Notes
  • Drug Policy
  • Rare Diseases
  • Mapping
  • Team Pharma Value
Special - The rules for CTS and CPR renewal AIFA

The renewal of the AIFA Commissions is imminent. What are the rules?

A settembre scadranno le Commissioni AIFA (CTS e CPR). NOMOS centro studi parlamentari e Pharma Value fanno il punto sulle regole per ...
Read more "
Rare Diseases Table

Who are the members of the technical table for rare diseases of the Ministry of Health

Il 21 giugno 2021 è stato istituito il Tavolo tecnico in tema di malattie rare. Il Tavolo riunisce esperti clinici e accademici, ...
Read more "

Privilege is invisible to the eyes.

Abbiamo chiesto alla Fondazione Giacomo Brodolini di aiutarci a ragionare sul privilegio, in questo mese del Pride dove i social si colorano ...
Read more "
ERN and rare diseases - report

ERN and rare diseases: the report of the Incisive Health Morning Club co-organised by Nomos, in collaboration with Pharma Value

Il 20 maggio si è tenuto l’Incisive Health Morning Club co-organizzato da Nomos Centro Studi Parlamentari e Pharma Value in collaborazione con ...
Read more "

Modification of national requirements in the blue box for medicines

AIFA ha pubblicato una comunicazione sull’aggiornamento circa i requisiti nazionali da inserire in Blue Box. C’è un impatto importante sulle attività regolatorie ...
Read more "

Easter 2021 - our best wishes

Il #TeamPharmaValue vi fa tantissimi auguri qualsiasi cosa festeggiate! Con questa animazione abbiamo voluto raccontare la nostra visione per la Pasqua 2021. ...
Read more "
1st OsMed Report on Parallel Import (IP) and Export of Medicines for Human Use by AIFA

1st OsMed Report on Parallel Import (IP) and Export of Medicines for Human Use by AIFA

I° Rapporto OsMed sull’importazione parallela (IP) ed esportazione dei medicinali per uso umano di AIFA Puoi rivederlo qui https://lnkd.in/dRgRGUV Nella presentazione di ...
Read more "

New application form for listing of medicines under Law 648/96

AIFA ha pubblicato un nuovo modulo per la richiesta di inserimento di medicinali nell’elenco ai sensi della legge 648/96; si evincono alcune ...
Read more "

Scientific Committee on Post-Market Surveillance of COVID-19 Vaccines (CSV-Covid19)

L’AIFA, il 14 dicembre 2020, ha costituito un comitato scientifico per la sorveglianza post-marketing dei vaccini COVID-19 (CSV-Covid19). Il CSV-Covid19 rimarrà in ...
Read more "
en_GB